Loading...

FULC FULCRUM THERAPEUTICS INC Management Changes 8-K Filing

FLCR

FLC

FULCRUM THERAPEUTICS INC

(FULC)

2024 8-K

Financial Results Announced

Corporate Update

Stock Offering Details

Clinical Trial Results

Quarterly Results

Corporate Presentation Update

Clinical Trials

Financial Statements

Agreement Termination

Financial Results

Financial Update

Agreement Termination

Financial Results

Workforce Reduction

Equity Exchange

Financial Results Announcement

Board Expansion and New Dir...

Collaboration and License A...

Financial Results Announcement

Financial Results Announcement

FDA Clinical Hold Lifted

Financial Results and Manag...

Annual Meeting Approval

Financial Results and Manag...

Resignation of CFO

Financial Results Announcement

Public Offering

Financial Condition

Management Changes

External Links:

James J. Collins resigned from the Board of Fulcrum Therapeutics, and Rachel King was appointed as a new director, receiving a stock option to purchase 60,000 shares at $3.64 each.

AI Assistant

FULCRUM THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.